# 510(k) Summary

# APR 2 8 2010

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter Name, Address, Contact

Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250

Contact person: Sarah Baumann Phone: (317) 521-3952 Fax: (317) 521-2324 Email: sarah.baumann@roche.com

Secondary contact: Stephanie Greeman Phone: (317) 521-2458   
Fax: (317) 521-2324   
Email: stephanie.greeman@roche.com

Date Prepared: October 23, 2009

# Device Name

Proprietary name: Elecsys® Testosterone II Immunoassay Common name: Testosterone II Assay Classification name: Testosterone Test System

# Device Description

The Elecsys Testosterone II immunoassay is based on a competitive test principle with streptavidin-coated microparticles and   
electrochemiluminescence detection. Results are determined using a   
calibration curve that is generated specifically on each instrument by a 2-point calibration and a master curve provided with the reagent bar code.   
The Elecsys Testosterone II reagent kit consists of a Reagent Pack (R1, R2, and M[Streptavidin-coated microparticles]).

# Substantial Equivalence

The Elecsys Testosterone II Test System is substantially equivalent to other devices legally marketed in the United States. We claim equivalency to the currently marketed Elecsys Testosterone Assay (K964889).

Substantial EquivalenceComparison

The following table compares the Elecsys Testosterone II Immunoassay with the predicate device.

<table><tr><td rowspan=1 colspan=3>Table 1. Testosterone Immunoassay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys Testosterone II Assay</td><td rowspan=1 colspan=1>Predicate DeviceElecsys Testosterone Assay(K964889)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Immunoassay for the in vitroquantitative determination oftestosterone in human serum andplasma. The electrochemiluminescenceimmunoassay &quot;ECLIA&quot; is intended foruse on Elecsys and cobas eimmunoassay analyzers.</td><td rowspan=1 colspan=1>Immunoassay for the in vitroquantitative determination oftestosterone in human serumand plasma. Theelectrochemiluminescenceimmunoassay &quot;ECLIA&quot; isintended for use on theBoehringer Mannheim Elecsys1010 and 2010 immunoassayanalyzers.</td></tr><tr><td rowspan=1 colspan=1>Indications forUse</td><td rowspan=1 colspan=1>Measurements of testosterone are usedin the diagnosis and treatment ofdisorders involving the male sexhormones (androgens), includingprimary and secondary hypogonadism,delayed or precocious puberty,impotence in males and, in femaleshirsutism (excessive hair) andvirilization (masculinization) due totumors, polycystic ovaries, andadrenogenital syndromes.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Protocol</td><td rowspan=1 colspan=1>Competition principle</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Detection Protocol</td><td rowspan=1 colspan=1>Electrochemiluminescenceimmunoassay (ECLIA)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Traceability/Standardization</td><td rowspan=1 colspan=1>ID-GC/MS (Isotope Dilution GasChromatography/Mass Spectrometry)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Human serum and plasma</td><td rowspan=1 colspan=1>Same</td></tr></table>

# 510(k) Summary, Continued

Substantial EquivalenceComparison (continued)

The following table compares the Elecsys Testosterone II Immunoassay with the predicate device.

<table><tr><td rowspan=1 colspan=3>Table 1. Testosterone Immunoassay Comparison, continued</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys Testosterone II Assay</td><td rowspan=1 colspan=1>Predicate DeviceElecsys Testosterone Assay(K964889)</td></tr><tr><td rowspan=1 colspan=1>InstrumentPlatform</td><td rowspan=1 colspan=1>Elecsys 2010(Request for CLIA categorizationhas been made to add theMODULAR ANALYTICS E170,cobas e 411, and cobas e 601analyzers according to theReplacement Reagent andInstrument Policy).</td><td rowspan=1 colspan=1>Elecsys 2010(Elecsys 1010, MODULARANALYTICS E170, cobas e 411,and cobas e 601 analyzers addedsubsequent to clearance)</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>2.5 - 1500 ng/dL(0.087 - 52.0 nmol/L)</td><td rowspan=1 colspan=1>2.0 - 1500 ng/dL(0.069 - 52.0 nmol/L)</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Testosterone II CalSet IICalibrators 1 and 2The stability, value assignment andmatrix is identical to TestosteroneCalSet II (cleared on K003411).</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>CalibrationInterval</td><td rowspan=1 colspan=1>Once per reagent lot andAfter 1 month (28 days) whenusing the same reagent lotAfter 7 days (when using thesame reagent kit on the analyzer)As required: e.g. quality controlfindings outside the specifiedlimits</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>PreciControl Universal 1 and 2(cleared on K090541)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent Stability</td><td rowspan=1 colspan=1>Unopened at 2-8°C - up to theexpiration date•After opening at 2-8°C - 12 weeksOnboard the analyzer - 8 weeks</td><td rowspan=1 colspan=1>SameAfter opening at 2-8°C - 8 weeksSame</td></tr></table>

# 510(k) Summary, Continued

# Substantial EquivalenceComparison (continued)

The following table compares the performance of the Elecsys Testosterone II Immunoassay with the predicate device.

<table><tr><td rowspan=1 colspan=3>Table 2. Testosterone Immunoassay Performance Comparison</td></tr><tr><td rowspan=1 colspan=1>Feat</td><td rowspan=1 colspan=1>Elecsys Testosterone II Assay</td><td rowspan=1 colspan=1>Predicate DeviceElecsys Testosterone Assay(K964889)</td></tr><tr><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>Elecsys 2010:Intermediate Precision (Total)18.5% CV @ 4.5 ng/dL8.4% CV @ 9.5 ng/dL3.2% CV @ 69.1 ng/dL2.8% CV @ 216 ng/dL2.8% CV @ 867 ng/dL3.4% CV @ 1300 ng/dL2.4% CV @ 1450 ng/dLRepeatability (Within-Run)10.2% CV @ 4.5 ng/dL4.7% CV @ 9.5 ng/dL2.1% CV @ 69.1 ng/dL1.9% CV @ 216 ng/dL2.6% CV @ 867 ng/dL1.2% CV @ 1300 ng/dL1.5% CV @ 1450 ng/dL</td><td rowspan=1 colspan=1>Elecsys 2010:Intermediate Precision (Total)7.4% CV @ 24 ng/dL2.6% CV @ 195 ng/dL2.2% CV @ 275 ng/dL1.6% CV @ 620 ng/dL1.7% CV @ 701 ng/dLRepeatability (Within-Run)4.6% CV @ 24 ng/dL1.7% CV @ 195 ng/dL1.4% CV @ 275 ng/dL0.9% CV @ 620 ng/dL1.1% CV @ 701 ng/dL</td></tr><tr><td rowspan=1 colspan=1>LoQ(FunctionalSensitivity</td><td rowspan=1 colspan=1>12.0 ng/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>LoB(Limit of Blank)</td><td rowspan=1 colspan=1>1.2 ng/dL</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>LoD(Limit ofDetection</td><td rowspan=1 colspan=1>2.5 ng/dL</td><td rowspan=1 colspan=1>2.0 ng/dL(Lower Detection Limit, LDL)</td></tr><tr><td rowspan=1 colspan=1>Limitations</td><td rowspan=1 colspan=1>The assay is unaffected by:Bilirubin: &lt; 30 mg/dLHemoglobin: &lt; 600 mg/dLIntralipid: &lt; 1000 mg/dLBiotin: &lt; 30 ng/mL</td><td rowspan=1 colspan=1>The assay is unaffected by:Bilirubin: &lt; 25 mg/dL•Hemoglobin: &lt; 1 g/dL (1000 mg/dL)Intralipid: &lt; 1500 mg/dLBiotin: &lt; 30 ng/mL</td></tr></table>

Substantial EquivalenceComparison (continued)   

<table><tr><td colspan="3">Table 2. Testosterone Immunoassay Performance Comparison, continued</td></tr><tr><td>Feature</td><td>Elecsys Testosterone II Assay</td><td>Predicate Device Elecsys Testosterone Assay (K964889)</td></tr><tr><td rowspan="7">Limitations, continued</td><td>In patients receiving therapy with high biotin doses (i.e. &gt; 5 mg/day), no sample should be taken until at least 8 hours after the last biotin administration.</td><td>In patients receiving therapy with high biotin doses (i.e. &gt; 5 mg/day), no sample should be taken until at least 8 hours after the last biotin administration.</td></tr><tr><td>No interference was observed from rheumatoid factors up to a concentration of 1000 IU/mL.</td><td></td></tr><tr><td>In vitro tests were performed with 18 commonly used pharmaceuticals. No interference with the assay was found. Three additional drugs were</td><td>In vitro tests were performed with 16 commonly used pharmaceuticals. No interference with the assay was found.</td></tr><tr><td>tested: heparin clexane, dexamethasone, and Nandrolone. A strong interaction with Nandrolone was found. Do not use samples from patients under Nandrolone treatment.</td><td></td></tr><tr><td>In isolated cases, elevated testosterone levels can be seen in samples from female patients</td><td></td></tr><tr><td>with end stage renal disease (ESRD).</td><td></td></tr></table>

The following table compares the performance of the Elecsys Testosterone II Immunoassay with the predicate device.

The following table compares the performance of the Elecsys Testosterone II Immunoassay with the predicate device.

Substantial EquivalenceComparison (continued)   
  

<table><tr><td colspan="3">Table 2. Testosterone Immunoassay Performance Comparison, continued</td></tr><tr><td>Feature</td><td>Elecsys Testosterone II Assay In rare cases, interference due to</td><td>Predicate Device Elecsys Testosterone Assay (K964889)</td></tr><tr><td>Limitations, continued</td><td>extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.</td><td>In rare cases interference due to extremely high titers of antibodies to streptavidin can occur. The risk of interference from potential immunological interactions between test</td></tr><tr><td rowspan="2">method.</td><td>For diagnostic purposes, the results should always be assessed in conjunction with the</td><td>components and rare sera have been minimized by the inclusion of suitable additives. For diagnostic purposes, the results should always be assessed in</td></tr><tr><td>patient&#x27;s medical history, clinical examination and other findings. Implausible elevated values in female samples should be verified by an extraction method or validated LC-MS/MS tandem</td><td>conjunction with the patient&#x27;s medical history, clinical examination and other findings.</td></tr></table>

Substantial EquivalenceComparison (continued)   

<table><tr><td colspan="4">Table 2. Testosterone Immunoassay Performance Comparison, continued</td></tr><tr><td>Feature</td><td>Elecsys Testosterone II Assay</td><td>Predicate Device Elecsys Testosterone Assay</td><td>(K964889)</td></tr><tr><td>Method Comparison</td><td>Four method comparison studies were performed to demonstrate the accuracy of the Elecsys Testosterone II assay. (1) Isotope dilution/liquid chromatographic-tandem mass spectrometry (ID/LC-MS/MS) was validated against the reference method, isotope-dilution/gas chromatography- mass spectrometry (ID-GC/MS).</td><td colspan="3">The Elecsys Testosterone assay was compared to the Coat-A-Count Total Testosterone Assay. A total of 71 clinical samples with testosterone values ranging from 20 - 1269 ng/dL were tested in singlicate.</td></tr><tr><td rowspan="8"></td><td rowspan="2">A total of 52 serum samples with</td><td>results.</td><td>The following table summarizes the</td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td rowspan="2">testosterone values ranging from 8 to 1383 ng/dL were measured.</td><td>n</td><td>Passing/Bablok</td><td>Least Squares</td></tr><tr><td>Range</td><td>71</td><td>71</td></tr><tr><td rowspan="2"></td><td>Slope</td><td>20-1269 ng/dL</td><td>20-1269 ng/dL</td></tr><tr><td></td><td>1.02</td><td>0.956</td></tr><tr><td>The following table summarizes the results.</td><td>y-int taw/r</td><td>-0.108 0.963</td><td>0.049</td></tr><tr><td></td><td></td><td colspan="3">0.963</td></tr><tr><td>n Range</td><td>52</td><td colspan="3" rowspan="3"></td></tr><tr><td></td><td>Deming Regression</td></tr><tr><td>Slope</td><td>8-1383 ng/dL</td></tr><tr><td>y-int Correlation</td><td>1.024 -0.060</td><td colspan="3"></td></tr></table>

The following table compares the performance of the Elecsys Testosterone II Immunoassay with the predicate device.

Substantial EquivalenceComparison (continued)   

<table><tr><td rowspan=1 colspan=6>Table 2. Testosterone Immunoassay Performance Comparison, continued</td></tr><tr><td rowspan=1 colspan=1>Feeature</td><td rowspan=1 colspan=4>Elecsys Testosterone II Assay</td><td rowspan=1 colspan=1>Predicate DeviceElecsys Testosterone Assay(K964889)</td></tr><tr><td rowspan=13 colspan=1>MethodComparisoncontinued</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td rowspan=1 colspan=1>Deming Regression</td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>55</td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>7.6-1383 ng/dL</td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>1.032</td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>y-int</td><td rowspan=1 colspan=1>-0.055</td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>r =0.999</td><td></td><td></td><td></td></tr><tr><td></td><td rowspan=1 colspan=2>Deming Regression</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=2>142</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=2>3-517 ng/dL</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=2>0.928</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>y-int</td><td rowspan=1 colspan=2>0.047</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=2>r =0.959</td><td></td><td></td></tr></table>

The following table compares the performance of the Elecsys Testosterone II Immunoassay with the predicate device.

Substantial EquivalenceComparison (continued)   

<table><tr><td rowspan=1 colspan=5>Table 2. Testosterone Immunoassay Performance Comparison, continued</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=3>,:      Elecsys Testosterone II Assay</td><td rowspan=1 colspan=1>Predicate DeviceElecsys Testosterone Assay(K964889)</td></tr><tr><td rowspan=19 colspan=1>MethodComparisoncontinued</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td rowspan=1 colspan=1>Deming Regression</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>239</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>6.3-1400 ng/dL</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.971</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>y-int</td><td rowspan=1 colspan=1>0.085</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>r=0.985</td><td></td><td></td></tr><tr><td></td><td rowspan=1 colspan=1>Deming Regression</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>148</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>2.5--926 ng/dL</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.984</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>y-int</td><td rowspan=1 colspan=1>-7.34</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>r=0.972</td><td></td><td></td></tr><tr><td></td><td rowspan=1 colspan=1>Deming Regression</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>387</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>2.5-1400 ng/dL</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.989</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>y-int</td><td rowspan=1 colspan=1>-2.87</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>r= 0.992</td><td></td><td></td></tr></table>

The following table compares the performance of the Elecsys Testosterone II Immunoassay with the predicate device.

Roche Diagnostics Corporation   
c/o Sarah Baumann   
9115 Hague Road   
P.O.Box 50410   
Indianapolis, IN 46250

# APR 2 3 2010

Re: k093421 Trade Name:Elecsys®Teststerone Issay Regulation Number: 21 CFR $\ S 8 6 2 . 1 6 8 0$ EP Regulation Name: Testosterone test system Regulatory Class: Class I, reserved Product Codes: CDZ Dated: April 19, 2010 Received: April 20, 2010

Dear Ms. Baumann:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Cc

Courtney C. Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indication for Use

510(k) Number (if known): k093421

$\otimes$ Device Name: Elecsys Testosterone II Assay

Indication For Use:

Immunoassay for the in vitro quantitative determination of testosterone in human serum and plasma. The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers.

Measurements of testosterone are used in the diagnosis and treatment of disorders involving the male sex hormones (androgens), including primary and secondary hypogonadism, delayed or precocious puberty, impotence in males and, in females hirsutism (excessive hair) and virilization (masculinization) due to tumors, polycystic ovaries, and androgenital syndromes.

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/44bd96e51eafb93895f067873d5bda658bd88947cabdb01328fc89e939be12ff.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety